Idazoxan

Major Depressive Disorder

Small moleculePhase 3Dormant

CC

45/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 35/ 100
Competitive Position: 65/ 100

Competitive context

235 Active assets in the Major Depressive Disorder cohort.

Asset / Sponsor	Phase	Rating
Risperdal Johns Hopkins University	Phase 4	BBB
Zelapar Corium Innovations, Inc.	Phase 4	BBB
S-Ketamine Janssen Research & Development, LLC	Phase 4	BBB
EDIVOXETINE Eli Lilly and Company	Phase 3	BBB
Opc-34712 Nova Scotia Health Authority	Phase 4	BBB

View all 50 →

Same molecule, other indications

Idazoxan is also rated in:

Molecular ImagingDormant

CC

Indicative ·

40 / 100

Healthy VolunteersDormant

C

Indicative ·

39 / 100

Alzheimer diseaseDormant

C

Indicative ·

35 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.